Genmab A/S Sponsored ADR $GMAB Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC grew its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 26.4% during the 1st quarter, Holdings Channel reports. The fund owned 4,414,550 shares of the company’s stock after acquiring an additional 921,700 shares during the period. Renaissance Technologies LLC’s holdings in Genmab A/S were worth $118,442,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Personal CFO Solutions LLC increased its position in Genmab A/S by 3.7% during the 1st quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock worth $292,000 after purchasing an additional 386 shares in the last quarter. Founders Capital Management raised its stake in Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Genmab A/S by 11.3% in the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after purchasing an additional 419 shares in the last quarter. CWM LLC lifted its holdings in Genmab A/S by 18.8% in the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after purchasing an additional 433 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its stake in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on GMAB. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Weiss Ratings downgraded shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. HC Wainwright raised their target price on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their target price for the stock from $32.00 to $43.00 in a research note on Wednesday. Finally, New Street Research set a $43.00 price target on Genmab A/S in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and an average price target of $39.28.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $28.87 on Friday. Genmab A/S Sponsored ADR has a twelve month low of $21.00 and a twelve month high of $35.43. The stock has a market capitalization of $18.00 billion, a P/E ratio of 21.87, a PEG ratio of 1.83 and a beta of 0.84. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The business’s fifty day moving average price is $26.82 and its 200 day moving average price is $28.32.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.